Market Overview

Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Related REGN
Stifel Remains Buyers Of Ophthotech As Year-End Binary Event Looms
2 Possible Scenarios For Opthotech
Biotech Forum Daily Digest: Biotech Has Tough Week; Will Conference Buoy Immunotherapy Concerns? (Seeking Alpha)
Related SNY
MannKind, Sanofi Reach Agreement on AFREZZA; Sanofi to Purchase $10.2M Worth of Insulin from MannKind
Can Cempra Clear Solithera Hurdle After FDA Reveal?
Sanofi said to be considering bid for Actelion (Seeking Alpha)

Regeneron (NASDAQ: REGN) spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi (NYSE: SNY), did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies.

Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares.

Regeneron shares spiked to a high of $145.81 on Thursday.

Posted-In: News Rumors M&A Movers


Related Articles (REGN + SNY)

View Comments and Join the Discussion!